

### What?

In up to 25 European hospitals, we test and evaluate an innovative new treatment that shall reduce inflammation and improve liver cell regeneration.

### Why?

10 million people worldwide suffer from decompensated cirrhosis. In its final stages, it leads to ACLF and far too often death.

G-CSF  
+  
TAK-242

### Who?

14 institutions led by



Dr. med. Cornelius Engelmann  
Charité - Berlin



Prof. Dr. Rajiv Jalan  
UCL - London



YouTube



a-tango.eu



@ATANGO\_H2020



/company/a-tango



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945096. This poster reflects only the view of the creators' and the European Commission is not responsible for any use that may be made of the information it contains. Coordinating Institution: EFCLIF, Barcelona